-
Urologic Oncology Chronicle 2026 | Professor Jun Guo and Leading Experts Highlight the Landmark Advances Reshaping GU Oncology
From the moment Charles Huggins first demonstrated the hormone dependence of prostate cancer in 1941, genitourinary oncology has evolved from an era of limited treatment possibilities into one defined by precision medicine and therapeutic innovation.
-
The 4th Urologic Oncology Clinical Research Conference | Professor Jun Guo on the Innovation Momentum and Future Direction of Chinese Genitourinary Oncology Research
The 4th Urologic Oncology Clinical Research Conference brought together leading experts, investigators, and innovators to review the latest progress in genitourinary oncology research in China. Alongside academic forums and international expert discussions, the meeting also released the 2025 Annual Report on Chinese Genitourinary Oncology Clinical Research, offering a comprehensive overview of the field’s recent development.
-
CSCO Guideline Preview | Professor Xinan Sheng Interprets the Core Advantages and Key Updates of the 2026 CSCO Renal Cancer Guidelines
The Chinese Society of Clinical Oncology (CSCO) Renal Cancer Guidelines have become one of the most influential and widely adopted clinical references in the field of kidney cancer in China. Built upon evidence-based medicine while remaining highly practical for everyday clinical use, the guidelines continue to evolve alongside rapid advances in renal cancer therapeutics.
-
4th Urologic Oncology Clinical Research Conference | Professor Jiwei Huang: Innovation and the Future of Non-Clear Cell RCC and UTUC
In recent years, both renal cell carcinoma and upper tract urothelial carcinoma (UTUC) have entered an era of rapid transformation, driven by advances in precision oncology, organ-preserving strategies, and systemic combination therapies.
Connecting Medical Expertise through Media
